Abstract
AbstractRapid molecular diagnostic tests have been critical in the response to the COVID-19 pandemic. It is important to evaluate the ability of these assays to identify variants of concern, particularly across varying collection and storage conditions. Nasal swabs positive for Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.167.2), Gamma (P.1), or Omicron (B.1.1.529) variants of concern (VOCs) were stored in TE buffer and viral transport media (VTM). We evaluated the sensitivity of the Cepheid Xpert® Xpress SARS-CoV-2 assay in detecting VOC samples and validated TE buffer for use with the assay. Testing of known VOC positives revealed no substantial reduction of PCR sensitivity. Comparison of TE and VTM samples also revealed no reduction in performance when using TE buffer, validating the use of TE buffer to store SARS-CoV-2 samples. SARS-CoV-2 VOCs collected and stored across various conditions can be detected by the Cepheid Xpert® Xpress SARS-CoV-2 assay.
Publisher
Cold Spring Harbor Laboratory
Reference12 articles.
1. Hinton, D. (2021, January 7). Xpert Xpress SARS-CoV-2—Letter of Authorization. https://www.fda.gov/media/136316/download
2. Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay
3. Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2
4. Comparison of Commercially;Journal of Clinical Microbiology,2020
5. Centers for Disease Control and Prevention (2022). COVID Data Tracker. US Department of Health and Human Services, CDC. https://covid.cdc.gov/covid-data-tracker